High levels of AOX1 are associated with better prognosis of bladder, renal, and pancreatic cancers [31,39], whereas high NMNAT1 expression is associated with poor survival in cancer patients with hepatocellular carcinoma [48]. Here, AOX1 is linked to hepatocellular carcinoma.